Citizens reiterates Market Outperform rating on Biomea Fusion after Phase 1 data
Citizens reaffirmed a Market Outperform rating on Biomea Fusion and set a $7.00 price target following Phase 1 results for the oral GLP candidate BMF‑650. The firm said the data validate BMF‑650 as active and well‑tolerated, supporting a potential partnership. Biomea’s stock was trading at $1.26 and the company completed enrollment in a Phase II diabetes trial with 64 participants, with results due in Q1 2027. The company also cancelled a planned public offering because of market conditions.
Why it matters
Citizens’ $7 target represents a 455.6% upside from the $1.26 price, which could attract buying interest. The validation of BMF‑650 may increase the likelihood of a strategic partnership and boost future revenue prospects.
Key facts
- 1Citizens reiterated a Market Outperform rating and a $7.00 price target on Biomea Fusion. investing.com
- 2The current share price was $1.26. investing.com
- 3Biomea Fusion’s market capitalization was $91.33 million. investing.com
- 4Phase 1 data validated BMF‑650 as an active and well‑tolerated oral GLP candidate. investing.com
- 5Biomea completed enrollment in its Phase II diabetes trial COVALENT‑211 with 64 participants. investing.com
- 6Results from the Phase II trial are expected in the first quarter of 2027. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.